1. Home
  2. Research
  3. Research Groups
  4. Translational Haematology

Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of ​​knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

Search for publications

Only original articles, editorials, guidelines.

  • Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, Rodríguez-Arbolí E, Bergua-Burgués JM, Vives S, Arnán M, Martínez Sánchez P, Herrera-Puente P, Serrano-López J, Rubio V, Marchante-Cepillo I, Cervera-Calvo M, Novo García A, Fernández Martín R, Gil Cortés C, Rodríguez-Medina C, Noriega-Concepción V, Alfonso-Piérola A, Loredo C, Antuña-Casal M, Boluda B, Cano-Ferri I, Acuña-Cruz E, Torres-Miñana L, Sánchez-García J, Bilbao C, Gómez-Casares MT, Martínez Cuadrón D, Montesinos P.

    Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.

    AMERICAN JOURNAL OF HEMATOLOGY . 101(9): 2258-2268.

    [doi:10.1002/ajh.70424]

  • Bose P, Ali H, Al-Ali HK, Garcia-Gutierrez V, Grosicki S, Grudeva-Popova Z, Harrison C, Hong J, Hou HA, Kwiatek M, Loschi M, Passamonti F, Patriarca A, Podoltsev N, Rampal R, Tantravahi S, Urian LG, Chai Y, Taverna P, Mark T, Sadiq A, Rangwala R, Vachhani P, Mascarenhas J.

    Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

    JOURNAL OF CLINICAL ONCOLOGY . 44(22): 2098-2109.

    [doi:10.1200/JCO-26-01080]

  • Barragán E, Gil JV, Ayala R, Chillón C, Soria E, Bilbao C, Larráyoz MJ, Prados de la Torre E, Solana A, Martínez-Cuadrón D, Rodríguez-Veiga R, Rodríguez-Arbolí E, Tormo M, Martínez P, Lavilla E, García-Garay MC, Arce O, Bergua J, Serrano J, Botella C, Lacalzada C, Almela-Gallego A, Lopez-Lorenzo JL, Valero M, Ibañez F, Foncillas MÁ, Rodriguez-Medina C, Olave M, Gómez-Correcha KG, Calderón MT, Bernal T, Labrador J, Oliva A, Madrigal MD, Hermosín L, Amador L, García-Belmonte D, Herrera P, Vives S, Perez-Encinas M, Algarra L, Casado S, Martínez-Chamorro C, Polo M, Balerdi A, Roldán A, Couto C, Pereiro M, Vanegas R, Llop M, Sargas C, Cionfrini A, Mendizábal Y, Sánchez J, Calasanz MJ, Gómez-Casares MT, Pérez-Simón JA, García-Sanz R, Martínez-López J, Montesinos P.

    Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

    Blood Neoplasia . 3(3): 100238-100238.

    [doi:10.1016/j.bneo.2026.100238]

  • Villegas A, Ropero P, González FA, Morado M, Menor M, de la Iglesia S, López-Rubio M, Salido EJ, Abío M, Senent ML, Recasens V, Vagace JM, Fonte C, Hernández-Rivas JM, Raya JM, Ríos P, Peri VL, Herrera KA, Tenorio MC, Riso LL, Tena J, Molina MA, Vara M, Rodríguez I, Ricard P, Gómez M, Dusacovschi OP, Vidán JM, Groiss J, Ferre Ó, Orbe I, López RM, Ugalde N, Hidalgo MI, Hinojosa C, Rodríguez AI, Herrera E, Murúzabal MJ, Del Carmen Hernández M, Marco JE, Benavente C, de Eritropatología GE.

    Beta-Thalassemia in Spain: Results From the National Thalassemia Registry and Molecular Analysis of Patients With Transfusion-Dependent Thalassemia.

    JOURNAL OF CLINICAL LABORATORY ANALYSIS . 40(14): .

    [doi:10.1002/jcla.70272]

  • Martin-Moro F, Alcoceba M, Romero S, Marquet-Palomanes J, Alonso-Castronuño D, Astibia-Mahillo B, Andreu R, Perez-Alonso R, Rodriguez-Martin E, De Ramon C, Solano I, Martin Garcia-Sancho A, Piris-Villaespesa M, Blanco O, Roldan-Santiago E, Garcia-Marco JA, Subira D, Navarro-Bailon A, Garcia-Cosio M, Garcia-Vela JA, Lopez-Jimenez J.

    Phenotypic Characterization of Richter Transformation and De Novo Diffuse Large B-Cell Lymphoma With or Without Monoclonal B-Cell Lymphocytosis.

    MODERN PATHOLOGY . 39(7): 101009-101009.

    [doi:10.1016/j.modpat.2026.101009]

  • Bailén R, Peña-Muñoz F, Bermúdez A, López-Corral L, Fox L, de Miguel C, Asensi P, Martín-González J, Pascual-Cascón MJ, Chinea A, González-Sierra P, Izquierdo I, Calbacho M, Vázquez J, Ceballos C, Morales-Curbelo A, Sánchez-Salinas A, Zanabili J, Sisinni L, González-Vicent M, Castilla L, Balsalobre P, Kwon M.

    Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy.

    Transplantation and Cellular Therapy . 32(7): .

    [doi:10.1016/j.jtct.2026.03.001]

  • Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E, Trigo F, Colorado M, Del Bernal Del Castillo T, Barragan E, Tormo M, Rodríguez Arbolí E, Serrano López J, García Boyero R, Castaño T, Herrera Puente P, Romero Riquelme MA, Sayas Lloris MJ, Algarra-Algarra L, Rodriguez-Medina C, Sossa Melo CL, Labrador Gomez J, Vives S, Salamero O, Amigo ML, Valero Nuñez M, Rojas C, Bass F, García-Fortes M, Vidriales Vicente B, Polo M, Benavente C, Madrigal MD, Espinoza M, Pérez-Encinas M, Amador Barciela ML, Bautista G, Solana-Altabella A, Cano-Ferri I, Colmenares R, García-Ramírez P, Ibáñez Alis F, Barrios García M, Rodríguez-Macías G, López M, Oliva Hernández AY, Cerveró CJ, Martínez-Cuadrón D, Chorão P, Bergua Burgues JM, Montesinos P.

    Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study.

    AMERICAN JOURNAL OF HEMATOLOGY . 101(7): 1692-1705.

    [doi:10.1002/ajh.70340]

  • Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, López-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH.

    Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.

    Lancet Haematology . 13(7): .

    [doi:10.1016/S2352-3026(26)00112-2]

  • Lenz G, Trnený M, Burke JM, Nowakowski GS, Fox CP, Chiappella A, Duell J, Jeon YW, Cheah CY, Westin J, Ye JZ, Caguioa PB, Belada D, Shin HJ, Oh SY, Amorim S, Ku M, Mocikova H, Jiménez JL, Gaidano G, Rosenwald A, Chiarle R, Colucci P, Ioannidis S, Cheng L, Vitolo U.

    Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial.

    LANCET . 407(10547): 2528-2541.

    [doi:10.1016/S0140-6736(26)00866-4]

  • Gomez-Llobell M, Shouval R, Brown S, Accav NG, Devlin S, Corona M, Rejeski K, Rivas-Delgado A, Luna A, Luttwak E, Raj SS, Alhomoud M, Sanz J, Einarsdottir S, Marcus R, Shimoni A, Ringelstein-Harlev S, Khatib H, Boardman AP, Lue J, Dahi P, Lin R, Scordo M, Falchi L, Shah GL, Palomba ML, Salles G, Park JH, Beyar-Katz O, Avigdor A, Perales MA.

    Landmark-Based Evaluations of Long-Term Outcomes After CD19 CAR T-cell Therapy in Large B-Cell Lymphoma.

    Transplantation and Cellular Therapy . 32(6): . Number of citations: 2

    [doi:10.1016/j.jtct.2026.02.058]

  • Albiol N, Martínez-Cibrián N, Pérez AI, Navarro-Velázquez S, Muzzi G, Oliver-Caldes A, Español-Rego M, Alserawan L, Montoro-Lorite M, Ramos C, Ayora P, Martin-López AÁ, Cabero A, Pérez-López E, García-Sancho AM, Baumann T, Sánchez-Pina JM, Chinea A, Fernández-Caldas P, Bastos-Oreiro M, Kwon M, Rodríguez-Lobato LG, Magnano L, Rivero A, Correa JG, Mozas P, Sánchez-Castañón M, Mata-Molanes JJ, Charry P, Álamo JR, Setoaín X, Rodríguez S, Olesti E, Sáez-Peñataro J, Fernández de Larrea C, Urbano-Ispizua Á, López-Guillermo A, Delgado J, González-Navarro EA, Juan M, Giné E, Ortiz-Maldonado V.

    Varnimcabtagene autoleucel (ARI-0001) in relapsed or refractory mantle cell lymphoma.

    HemaSphere . 10(5): .

    [doi:10.1002/hem3.70388]

  • Zabaleta A, Tamariz-Amador LE, Kostopoulos IV, Sklavenitis Pistofidis R, Smits F, Rodriguez-Otero P, Roncal C, Aranha MP, Žihala D, Machu M, Tsakirakis N, Bakouros P, Tsitsilonis O, Solia I, Moreno C, Maia C, Martin-Sanchez E, Pérez JJ Sr, Encinas C, Ríos-Tamayo R, Oriol A, Blanchard MJ, de Arriba F, González-García E, Lakhwani S, Sureda A, Cabañas V, Escalante F, Carrillo-Cruz E, Pérez-Montaña A, Ocio EMM, Bargay J, Orfao A, Jelínek T, Ghobrial IM, Mutis T, Zweegman S, Terpos E, Kastritis E, Martínez-López J, Lahuerta JJ, Fernández de Larrea C, Rosiñol L, Bladé J, Mateos MV, San-Miguel JF, Cedena MT, Puig N, Paiva B.

    Immune biomarkers of increased infection risk in multiple myeloma.

    BLOOD . 147(18): 2081-2088. Number of citations: 2

    [doi:10.1182/blood.2025031744]

  • Alonso-Dominguez JM, Castaño-Bonilla T, Gil C, Serrano-Lopez J, Martinez-Sanchez P, Herrera P, Garcia-Boyero R, Rodriguez-Arboli E, Brioso-Infante J, Benavente C, Lavilla-Rubira E, Tormo M, Sayas-Lloris MJ, Lainez-Gonzalez D, Serrano-Lopez J, Amigo ML, Algarra L, Unamunzaga A, Alonso-Alonso JM, Garcia-Garay MC, Callejas-Charavia M, Roldan-Perez A, Cornago-Navascues J, Valero-Nuñez M, Alfonso-Pierola A, Perez-Santaolalla E, Sobas M, Romero-Riquelme M, Lopez M, Galvez K, Rodríguez-Veiga R, Barragan E, Ayala R, Solana-Altabella A, Lloret-Madrid P, Montesinos P.

    Reassessing adverse prognosis of acute myeloid leukemia harboring BCR::ABL1 in the era of tyrosine kinase inhibitors: A real-world analysis from the PETHEMA registry.

    CANCER . 132(8): .

    [doi:10.1002/cncr.70353]

  • Bermejo-Olivera FJ, Velasco-Sidro M, Íñiguez-García R, Arroyo-Sánchez D, Pleguezuelo-Garrote DE, Serrano-Blanco M, Fernández-Galván A, Baumann T, López-Jiménez FJ, Revilla-Sánchez E, Paz-Artal E, Allende LM, Cabrera-Marante O.

    First Case of TAP1 Deficiency with EBV B-Cell Lymphoma Treated with Cellular Immunotherapy.

    JOURNAL OF CLINICAL IMMUNOLOGY . 46(1): .

    [doi:10.1007/s10875-026-01997-0]

  • García-Cadenas I, Guerreiro M, Yañez L, Chorao P, Martin F, Suárez-Lledó M, Pérez A, Tomás LG, López J, Marsal J, Romero N, Huguet M, Zabalza A, González-Vicent M, Vázquez L, Silva P, Gil D, Micó-Cerdà M, Sánchez P, Filaferro S, Balsalobre P, Jiménez-Ubieto A, Martino R, Piñana JL.

    Evolving Patterns of EBV-Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH-TC Study.

    EUROPEAN JOURNAL OF HAEMATOLOGY . 116(4): 450-457.

    [doi:10.1111/ejh.70109]

  • Santaliestra M, Garrote M, Fernández-Rodríguez MC, Vélez P, Senín A, Arellano-Rodrigo E, Garcia-Gisbert N, Longarón R, Pérez-Encinas M, Caballero-Navarro G, Noya-Pereira MS, Cuevas B, Gómez-Casares MT, Stuckey R, Carreño-Tarragona G, Ferrer-Marin F, Cortés MA, Magro E, Mata I, Angona A, Pérez R, Fox ML, Pastor-Galán I, Sastre P, Triguero A, García-Gutierrez V, Hernández-Boluda JC, Bellosillo B, Alvarez-Larran A.

    Response to therapy and prognosis according to molecular characterization in CALR-mutated essential thrombocythemia.

    HemaSphere . 10(3): .

    [doi:10.1002/hem3.70325]

  • Rodríguez-Aliberas M, Alonso IR, Rey EG, Llorente AV, Vera CF, Mingot-Castellano ME, Alcaina PS, García-Gala JM, Escriche AP, Cabrera JLB, Escoll VP, López RC, Rodríguez MF, Calafat MG, Whilhemi PR, Camps CP, Acosta LD, Álvarez MA, Albanell JF, Risco MBM, Jiménez GM, Canto JGD, Infante LR, García MDCH, Oyarzabal AP, Galán MF, Casado ED, Molina VC, Muñiz-Diaz E.

    Irregular antibodies in pregnancy during the universal anti-RHD prophylaxis era: a survey of Spanish Hospitals.

    Blood Transfusion . 24(2): 106-116.

    [doi:10.2450/BloodTransfus.1170]

  • Giménez E, Rodriguez-Belenguer P, Solano C, Vázquez L, Martino R, Cámara R, Rovira M, Espigado I, Calvo CM, López-Jiménez J, Pérez A, Bermúdez A, Saldaña R, Heras I, González-Huerta AJ, Torrado T, Bautista G, Perera-Álvarez MDM, González-Pinedo L, Barba P, Cuesta MÁ, Chorão P, Basalobre P, Navarro D, García-Cadenas I, Piñana JL.

    Unveiling CMV Risk Signatures After Allogeneic Stem Cell Transplantation Through Machine Learning Approaches: A Multicenter Analysis From the GETH-TC.

    JOURNAL OF MEDICAL VIROLOGY . 98(3): .

    [doi:10.1002/jmv.70867]